Oramed Investor Suit Seeks To Claw Back Stock Awards
Law360 (March 24, 2021, 9:56 PM EDT) -- An Oramed Pharmaceuticals stockholder filed a proposed class action Wednesday in Delaware's Chancery Court seeking to recover more than 1.3 million shares she claims the company's board of directors improperly awarded its members and others after incorrectly reporting the results of stockholder votes on an employee stock incentive plan.
Plaintiff Renee De Felice brought direct and derivative claims on behalf of herself, similarly situated stockholders and Oramed Pharmaceuticals Inc. against the New York-based company's directors and executives, alleging they violated company bylaws in how they tabulated the stockholder votes and that the shares they subsequently awarded under the plans are invalid....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!